Britain’s regulator approves a dose of up to 7.2 mg of semaglutide per week, up from 2.4 mg.

By Sriparna Roy Jan 23 (Reuters) - Novo Nordisk's Wegovy pill was prescribed more than 18,000 times in the U.S. in the first ...

The oral weight-loss drug introduced by Novo Nordisk this year in the U.S. is quickly being adopted. Analysts pointed to data from Symphony Health which showed that weekly prescriptions for the oral ...

By Bhanvi Satija and Maggie Fick LONDON, Jan 16 (Reuters) - Novo Nordisk's Wegovy weight-loss pill has made an encouraging ...

Monthly injections, once-daily pills, and even lifelong gene therapies could soon become options for people looking to lose ...

FDA-approved semaglutide drug is the first GLP-1 pill for weight loss available in the U.S., according to drugmaker Novo Nordisk.

The VanEck Pharmaceutical ETF (NYSEARCA:PPH) has surged 26% over the past year, driven almost entirely by the weight-loss ...

Novo Nordisk ( NVO +1.68%) was once the top player in the weight loss drug market. The company's medicine, Wegovy, ...

Novo Nordisk announced Jan. 5 it will begin offering its Wegovy weight loss pill to self-paying patients in the United States, expanding access to the popular GLP-1 medication beyond injections.

Two weeks after securing approval from the U.S. Food and Drug Administration, a once-daily pill version of Novo Nordisk‘s popular GLP-1 weight loss drug Wegovy officially hit the market. In a Jan. 5 ...

Novo Nordisk executive Dave Moore touted high interest in Wegovy's oral version of its injectable GLP-1 weight-loss ...

Novo Nordisk's Wegovy pill was prescribed 18,410 times in the U.S. in the first full week after its launch in an encouraging ...